From the FDA Drug Label
AUSTEDO XR extended-release tablets and AUSTEDO tablets are formulated with deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration. The brand name of deutetrabenazine is AUSTEDO or AUSTEDO XR 1.
From the Research
The brand name for deutetrabenazine is Austedo. Austedo is a medication approved by the FDA for treating chorea associated with Huntington's disease and tardive dyskinesia, as indicated in the study by 2. It works by depleting monoamines like dopamine from nerve terminals, which helps reduce the involuntary movements characteristic of these conditions. Deutetrabenazine is a deuterated form of tetrabenazine, meaning hydrogen atoms have been replaced with deuterium atoms, which slows down metabolism of the drug and allows for less frequent dosing and potentially fewer side effects than its predecessor, as shown in the pharmacokinetic study by 3.
Key Points
- Deutetrabenazine is used to treat chorea in Huntington's disease and tardive dyskinesia.
- The brand name for deutetrabenazine is Austedo, as mentioned in the study by 2.
- Deutetrabenazine has a superior pharmacokinetic profile compared to tetrabenazine, with a longer half-life and lower peak-to-trough fluctuations, as demonstrated in the study by 3.
- Patients typically take Austedo twice daily with food, with dosing individualized based on response and tolerability.
- Common side effects may include sedation, dizziness, and potential worsening of depression or suicidal thoughts, so careful monitoring is necessary, especially when initiating treatment, as noted in the safety analysis by 4.
Safety and Efficacy
The safety and efficacy of deutetrabenazine have been established in several clinical trials, including the studies by 5, 4, and 6. These studies have shown that deutetrabenazine is generally well-tolerated and effective in reducing the symptoms of chorea in Huntington's disease and tardive dyskinesia. The study by 6 also highlighted the clinical utility of deutetrabenazine as a treatment option for these conditions.
Dosage and Administration
Deutetrabenazine is typically administered orally, twice daily, with food. The dosage is individualized based on response and tolerability, with a maximum recommended dose of 72 mg daily, as indicated in the study by 6.
Monitoring and Precautions
Careful monitoring is necessary when initiating treatment with deutetrabenazine, especially in patients with a history of depression or suicidal thoughts. Regular follow-up appointments and monitoring of side effects are crucial to ensure the safe and effective use of this medication, as noted in the study by 4.